Injection-free vaccination technique could address global vaccine challenge for HIV, malaria
Scientists demonstrate the ability to deliver a dried live vaccine to the skin without a traditional needle
4-Feb-2013 - Scientists at King's College London have demonstrated the ability to deliver a dried live
vaccine to the skin without a traditional needle, and shown for the first time that this technique is powerful enough to enable
specialised immune cells in the skin to kick-start the immunising properties of the vaccine.
Funded by the Bill & Melinda Gates Foundation and published today in Proceedings of the National Academy of Sciences,
researchers say although it is an early study this important technical advance offers a potential solution to the challenges of
delivering live vaccines in resource-limited countries globally, without the need for refrigeration. A cheaper alternative to
hypodermic needles, it would also remove safety risks from needle contamination and the pain-free administration could lead
to more people taking up a vaccination. The researchers add that it could have an impact beyond infectious disease
vaccination programmes, for example managing autoimmune and inflammatory conditions such as diabetes.
HIV, malaria and TB represent major global health challenges. Although promising research is underway to develop vaccines
for these diseases, considerable stumbling blocks remain for countries where transporting and storing live vaccines in a continuously
cold environment (around 2°C to 8°C or below) would not be possible. If a cold chain cannot be maintained for a live vaccine there
is a high risk it could become unsafe and lose effectiveness.
The team at King's used a silicone mould developed by US company TheraJect to create a microneedle array - a tiny disc
with several micro-needles made of sugar which dissolve when inserted into the skin. The team formulated a dried version of a live
modified adenovirus-based candidate HIV vaccine in sugar (sucrose) and used the mould to create the microneedle array. They
found that the dried live vaccine remained stable and effective at room temperature.
To test the effectiveness of the microneedle array, they applied it to mice. Using imaging (in collaboration with
Professor Frederic Geissmann, King's College London) they observed how the vaccine dissolved in the skin and were able to
identify for the first time exactly which specialised immune cells in the skin 'pick up' this type of vaccine and
activate the immune system. The researchers found the first evidence that a sub-set of specialised dendritic
cells in the skin were responsible for triggering this immune response.
When compared with a traditional needle vaccine method, the immune response generated by the dried microneedle vaccine
(kept at room temperature) was equivalent to that induced by the same dose of injected liquid vaccine that had been preserved at -80°C.
Dr Linda Klavinskis from the Peter Gorer Department of Immunobiology at King's College London, said: 'We have shown that it
is possible to maintain the effectiveness of a live vaccine by drying it in sugar and applying it to the skin using microneedles - a
potentially painless alternative to hypodermic needles. We have also uncovered the role of specific cells in the skin which
act as a surveillance system, picking up the vaccine by this delivery system and kick-starting the body's immune processes.
'This work opens up the exciting possibility of being able to deliver live vaccines in a global context, without the need
for refrigeration. It could potentially reduce the cost of manufacturing and transportation, improve safety (as there would be no loss
in potency), and avoids the need of hypodermic needle injection, reducing the risk of transmitting blood-borne disease from
contaminated needles and syringes.
'This new technique represents a huge leap forward in overcoming the challenges of delivering a vaccination programme
for diseases such as HIV and malaria. But these findings may also have wider implications for other infectious disease vaccination
programmes, for example infant vaccinations, or even other inflammatory and autoimmune conditions such as diabetes.'
###
The published study from King's College London is part of a larger project funded by the Bill & Melinda Gates Foundation linking
other groups, including those at Imperial College London and Royal Holloway University of London, who are working on other aspects
of HIV vaccination.
CONTACT
Katherine Barnes
International PR Manager
King's College London
Tel: +44 207 848 3076
Email: katherine.barnes@kcl.ac.uk
Notes to editors
*Images available on request*
This work was supported by the Bill & Melinda Gates Foundation.
The team also used equipment made available by the National Institute for Health Research (NIHR) Biomedical Research Centre at Guy's and St Thomas' NHS Foundation Trust and King's College London.
About King's College London
King's College London is one of the top 30 universities in the world (2011/12 QS World University Rankings), and the fourth oldest in England. A research-led university based in the heart of London, King's has nearly 23,500 students (of whom more than 9,000 are graduate students) from nearly 140 countries, and some 6,000 employees. King's is in the second phase of a £1 billion redevelopment programme which is transforming its estate.
King's has an outstanding reputation for providing world-class teaching and cutting-edge research. In the 2008 Research Assessment Exercise for British universities, 23 departments were ranked in the top quartile of British universities; over half of our academic staff work in departments that are in the top 10 per cent in the UK in their field and can thus be classed as world leading. The College is in the top seven UK universities for research earnings and has an overall annual income of nearly £450 million.
King's has a particularly distinguished reputation in the humanities, law, the sciences (including a wide range of health areas such as psychiatry, medicine, nursing and dentistry) and social sciences including international affairs. It has played a major role in many of the advances that have shaped modern life, such as the discovery of the structure of DNA and research that led to the development of radio, television, mobile phones and radar. It is the largest centre for the education of healthcare professionals in Europe; no university has more Medical Research Council Centres. Source:http://www.eurekalert.org/pub_releases/2013-02/kcl-ivt020413.php
For more HIV and AIDS News visit...
Positively Positive - Living with HIV/AIDS:
HIV/AIDS News
|
